Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 13.17% is 31% below its 2-year average of 19.09%, near the low end of its 2-year range (9.74%–47.02%).
As of the fiscal period ended Tuesday, June 30, 2026. 13.46% above its 12-month average of 11.61%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 13.17%.
DEBT TO ASSETS RATIO
13.17%
DEBT TO ASSETS RATIO AVG TTM
11.61%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+13.46%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.12%
median of 395 covered companies
CURRENT VS SECTOR MEDIAN
+10875.49%
vs the sector median at left
CeriBell, Inc.
Market Cap
$943.26M
Debt to Assets Ratio
13.17%
TTM Avg
11.61%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$922.50M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$903.13M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$985.79M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$989.05M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$867.60M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$852.55M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $943.26M | 13.17% | 11.61% | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 0.01% | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $915.95M | 0.39% | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | 0.00% | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | 0.01% | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | 0.02% | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | 0.05% | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | 0.02% | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $844.28M | 0.06% | N/A | N/A | N/A |
Debt/Assets
13.2%
Debt/Equity
0.17
Current Ratio
9.18
Interest Coverage
-30.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 13.17% |
| 2026-03-31 | 12.42% |
| 2025-12-31 | 11.38% |
| 2025-09-30 | 10.70% |
| 2025-06-30 | 10.38% |
| 2025-03-31 | 10.19% |
| 2024-12-31 | 9.74% |
| 2024-09-30 | 47.02% |
| 2024-06-30 | 41.79% |
| 2023-12-31 | 24.11% |
